Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 48.50
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

9 Jun 2020 07:00

RNS Number : 3194P
Cambridge Cognition Holdings PLC
09 June 2020
 

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Grant of Options

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 8 June 2020, the Company granted options ("Options") over a total of 1,040,041 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's EMI option scheme and the Company's unapproved option scheme.

Of these Options:

- 688,020 were granted to Persons Discharging Managerial Responsibilities ("PDMRs") on behalf of the Company;

Name

Role

Number of Options Granted

Total number of Options held following Grant

Total number of Ordinary Shares

currently held

Percentage of Current Issued Share Capital currently held

Matthew Stork

Chief Executive Officer

196,429

529,287

125,000

0.40%

Nicholas Walters

Chief Financial Officer

60,000

60,000

300,826

0.97%

Jennifer Barnett

Chief Scientific Officer

66,365

182,865

7,213

Under 0.01%

Ricky Dolphin

Chief Technology Officer

93,521

240,634

-

-

Fiona Cree

Chief Operating Officer

76,500

156,857

-

-

Richard Cooper

Chief Commercial Officer

111,786

111,786

-

-

Malcolm Gates

Director of Group Finance

83,419

199,206

-

-

 

- 352,021 were granted to other employees of the Company.

Of the Options granted to PDMRs:

1. 641,429 are exercisable at a price of 28 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 77.5 pence, with the price on the last day of that period being at least 70 pence, and the last day of this period being no later than 31 May 2023; and

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 115 pence, with the price on the last day of that period being at least 105 pence, and the last day of this period being no later than 31 May 2023.

2. 45,091 have been issued under a salary sacrifice scheme and are exercisable at a price of 1 pence per Ordinary Share from 1 November 2021 until 31 October 2023. These options were issued in exchange for a portion of salary being sacrificed amounting to £10,043 between May and July 2020.

3. The remaining 1,500 options are exercisable at a price of 1 pence per Ordinary Share from two years following the date of award until the tenth anniversary of the date of award. All of these Options are granted over shares already in issue and held by Cambridge Cognition Trustees Limited on behalf of the Employee Benefit Trust.

Of the options granted to other employees of the Company:

1. 250,000 are exercisable at a price of 28 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 77.5 pence, with the price on the last day of that period being at least 70 pence, and the last day of this period being no later than 31 May 2023; and

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 115 pence, with the price on the last day of that period being at least 105 pence, and the last day of this period being no later than 31 May 2023.

2. 97,521 have been issued under a salary sacrifice scheme and are exercisable at a price of 1 pence per Ordinary Share from 1 November 2021 until 31 October 2023. These options were issued in exchange for a portion of salary being sacrificed amounting to £24,199 between May and July 2020.

3. The remaining 4,500 options are exercisable at a price of 1 pence per Ordinary Share from two years following the date of award until the tenth anniversary of the date of award. All of these Options are granted over shares already in issue and held by Cambridge Cognition Trustees Limited on behalf of the Employee Benefit Trust.

Following the grant of Options, the total number of Options outstanding over unissued Ordinary Shares is 2,220,219, representing approximately 7.12% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Names

Jennifer Barnett - Chief Scientific Officer

Fiona Cree - Chief Operating Officer

Ricky Dolphin - Chief Technology Officer

Richard Cooper - Chief Commercial Officer

Malcolm Gates - Director of Group Finance

Nicholas Walters - Chief Financial Officer

Matthew Stork - Chief Executive Officer

2.

Reason for the Notification

a)

Position/status

See 1(a) above for positions - all classified as PDMRs of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

In each case, the grant of Options over Ordinary Shares on 8 June 2020

 

Identification code

GB00B8DV9647

b)

Nature of the transaction

Grant of Options over Ordinary Shares

 

c)

Price(s) and volume(s)

Price: n/a

Volumes:

Matthew Stork - 196,429 Options

Nicholas Walters - 60,000 Options

Jennifer Barnett - 66,365 Options

Ricky Dolphin - 93,521 Options

Fiona Cree - 76,500 options

Richard Cooper - 111,786 Options

Malcolm Gates - 83,419 Options

d)

Aggregated information:

· Aggregated volume

· Price

n/a

e)

Date of the transaction

8 June 2020

f)

Place of the transaction

Outside a trading venue

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

Enquiries

Cambridge Cognition Holdings PLC

Matthew Stork, Chief Executive Officer

Nick Walters, Chief Financial Officer

Tel: 01223 810 700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Tel: 020 7220 0500

Geoff Nash / Simon Hicks

(Corporate Finance)

Alice Lane/ Manasa Patil

(Corporate Broking)

 

Dowgate Capital Limited (Joint Broker)

David Poutney/ James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

IFC Advisory Limited (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe/ Graham Herring/ Zach Cohen

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDVLFBBQLBBBE
Date   Source Headline
25th Nov 20197:00 amRNSCambridge Cognition expands eCOA and wins contract
31st Oct 20194:17 pmRNSGrant of Options
29th Oct 20197:00 amRNSHolding(s) in Company
25th Oct 20197:00 amRNSAlzheimer's drug potential for Cambridge Cognition
26th Sep 201912:15 pmRNSDirector/PDMR Shareholding
23rd Sep 201910:42 amRNSDirector/PDMR Shareholding
19th Sep 20197:00 amRNSInterim Results
30th Aug 20194:59 pmRNSHolding(s) in Company
29th Aug 20192:20 pmRNSHolding(s) in Company
27th Aug 20197:00 amRNSTrading Update
14th Aug 201910:10 amRNSDr. Nick Kerton
12th Aug 20197:00 amRNSExpansion in Chinese market
22nd Jul 20197:00 amRNSNotice of Results
19th Jul 20197:00 amRNSNew Commercial Partnership for NeuroVocalix
1st Jul 20197:00 amRNSAppointment of Non-Executive Director
11th Jun 20197:00 amRNSCapital Markets Day
23rd May 20192:35 pmRNSResult of AGM and Board Changes
1st May 20197:00 amRNSPosting of Annual Report & Notice of AGM
25th Apr 20197:00 amRNSBoard Changes
17th Apr 20197:00 amRNSGrant of Options
19th Mar 20197:00 amRNS£1.3m digital health contract win
14th Mar 20198:54 amRNSHolding(s) in Company
14th Mar 20197:00 amRNSHolding(s) in Company
12th Mar 20195:23 pmRNSDirector/PDMR Shareholding
12th Mar 201911:59 amRNSHolding(s) in Company
7th Mar 20197:02 amRNSAppointment of Chief Operating Officer
7th Mar 20197:01 amRNSFundraising to raise £2.5 million
7th Mar 20197:00 amRNSPreliminary Results
31st Jan 20197:00 amRNSFirst Partnership in India and New Product Launch
19th Dec 20187:00 amRNSTrading update and notice of results
14th Nov 20187:00 amRNSContract win in growing eCOA revenue stream
20th Sep 20187:00 amRNSHalf Yearly Report
19th Sep 20187:00 amRNSCompany signs first NeuroVocalix contract
13th Sep 20187:00 amRNSNeuroVocalixT platform ready for clinical trials
1st Aug 20187:00 amRNSCANTAB incorporated in population health platform
20th Jun 20187:00 amRNSNew product to improve workplace mental health
7th Jun 20187:00 amRNSPartnership to tackle growing mental health need
31st May 20187:00 amRNSNew client signs with Cognition Kit software
24th May 201812:24 pmRNSResult of AGM
9th May 201811:34 amRNSHolding(s) in Company
3rd May 20187:00 amRNSDirector/PDMR Shareholding
2nd May 20187:00 amRNSPosting of Annual Report & Notice of AGM
12th Apr 20181:20 pmRNSHolding(s) in Company
12th Apr 201810:20 amRNSHolding(s) in Company
10th Apr 20187:00 amRNSRecruitment contracts show strong growth
26th Mar 20187:00 amRNSMajor Contract Win and Funding Award
22nd Mar 201811:05 amRNSSecond Price Monitoring Extn
22nd Mar 201811:00 amRNSPrice Monitoring Extension
22nd Mar 20187:00 amRNSFinal Results
1st Mar 20187:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.